Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
42.63-0.08 (-0.19%)
At close: 04:00PM EDT
42.63 0.00 (0.00%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close42.71
Open42.73
Bid42.57 x 100
Ask42.64 x 300
Day's range42.60 - 42.86
52-week range19.59 - 43.59
Volume914,500
Avg. volume1,405,168
Market cap7.754B
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Yahoo Finance Video

    AbbVie acquiring Cerevel Therapeutics in $8.7B deal

    AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.